Impact BioMedical Inc. (IBO) stock
IBONYSEPharmaceutical PreparationsFiscal year ends December 31
$3.06+0.38 (+14.18%)
Close on Oct 19, 2026Market cap $26.14MP/E –Yield –
Impact BioMedical r&d expenses
Research and development expenses are spending on new products and technology.
Impact BioMedical's R&D Expenses for the twelve months ending Sep 30, 2026 was $267.00K. For fiscal 2025 it was $340.00K, up 22.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $340.00K | +22.3% |
| FY2024 | Dec 31, 2024 | $278.00K | -83.5% |
| FY2023 | Dec 31, 2023 | $1.69M | +37.4% |
| FY2022 | Dec 31, 2022 | $1.23M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $35.00K | -32.7% |
| Q2 FY2026 | Jun 30, 2026 | $76.00K | +1.3% |
| Q1 FY2026 | Mar 31, 2026 | $46.00K | -55.3% |
| Q4 FY2025 | Dec 31, 2025 | $110.00K | +34.1% |
| Q3 FY2025 | Sep 30, 2025 | $52.00K | -57.0% |
| Q2 FY2025 | Jun 30, 2025 | $75.00K | -59.0% |
| Q1 FY2025 | Mar 31, 2025 | $103.00K | -83.7% |
| Q3 FY2024 | Sep 30, 2024 | $82.00K | -77.0% |
| Q2 FY2024 | Jun 30, 2024 | $121.00K | -54.5% |
| Q1 FY2024 | Mar 31, 2024 | $183.00K | +2.2% |
| Q4 FY2023 | Dec 31, 2023 | $630.00K | +20.7% |
| Q3 FY2023 | Sep 30, 2023 | $357.00K | +8.2% |
| Q2 FY2023 | Jun 30, 2023 | $266.00K | +29.1% |
| Q1 FY2023 | Mar 31, 2023 | $179.00K | – |
| Q4 FY2022 | Dec 31, 2022 | $522.00K | – |
| Q3 FY2022 | Sep 30, 2022 | $330.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $206.00K | – |
See a number that looks wrong?